Combined hormonal contraceptives use among women with contraindications according to the WHO criteria: A systematic review.
Sex Reprod Healthc
; 27: 100587, 2021 Feb.
Article
in En
| MEDLINE
| ID: mdl-33545506
ABSTRACT
INTRODUCTION:
Combined hormonal contraceptives (CHC), containing estrogen, remain the most popular choice of contraceptive among women. While the method offers many benefits, the use of CHC involves potential health risks. The aim of this study was to analyze the available evidence on the prevalence of CHC use among women with contraindications to their use according to the WHO recommendations (2015).METHODS:
Pubmed, Lilacs, and Web of Sciences databases were searched. Selection was based on articles that described the use of combined hormonal contraceptives according to the characteristics that are listed as contraindications in WHO medical eligibility criteria for contraceptive use.RESULTS:
A total of 4363 articles were identified and 18 articles were selected for the review. The most prevalent contraindications against use of CHC were systemic arterial hypertension, migraine, and smoking (in women aged 35â¯years or older). Prevalence rates of contraindications against use of CHC ranged from 5.9% to 41.9%.CONCLUSIONS:
A high proportion of women still use CHC when contraindicated to do so according to the WHO criteria. Health policies should focus on highlighting the importance of a detailed health evaluation on CHC candidates, to reduce the proportion of inappropriate prescriptions.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Smoking
/
Contraceptives, Oral, Combined
Type of study:
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Limits:
Female
/
Humans
Language:
En
Journal:
Sex Reprod Healthc
Journal subject:
ENFERMAGEM
/
MEDICINA REPRODUTIVA
/
OBSTETRICIA
Year:
2021
Type:
Article